15 September 2021 in Science Translational Medicine
Static storage of donor lungs at 10°C enhances mitochondrial protection and is a clinically feasible option to extend viable lung preservation times.
16 February 2022 in Science Translational Medicine
Donor organ allocation is dependent on ABO matching, restricting the opportunity for some patients to receive a life-saving transplant. The enzymes FpGalNAc deacetylase and FpGalactosaminidase, used in combination, have been described to effectively convert group A (ABO-A) red blood cells (RBCs) to group O (ABO-O). Here, we study the safety and preclinical efficacy of using these enzymes to remove A antigen (A-Ag) from human donor lungs using ex vivo lung perfusion (EVLP). First, the ability of these enzymes to remove A-Ag in organ perfusate solutions was examined on five human ABO-A1 RBC samples and three human aortae after static incubation. The enzymes removed greater than 99 and 90% A-Ag from RBCs and aortae, respectively, at concentrations as low as 1 μg/ml. Eight ABO-A1 human lungs were then treated by EVLP. Baseline analyses of A-Ag in lungs revealed expression predominantly in the endothelial and epithelial cells. EVLP of lungs with enzyme-containing perfusate removed over 97% of endothelial A-Ag within 4 hours. No treatment-related acute lung toxicity was observed. An ABO-incompatible transplant was then simulated with an ex vivo model of antibody-mediated rejection using ABO-O plasma as the surrogate for the recipient circulation using three donor lungs. The treatment of donor lungs minimized antibody binding, complement deposition, and antibody-mediated injury as compared with control lungs. These results show that depletion of donor lung A-Ag can be achieved with EVLP treatment. This strategy has the potential to expand ABO-incompatible lung transplantation and lead to improvements in fairness of organ allocation.
1 March 2022 in The Journal of Heart and Lung Transplantation
19 March 2026 in The Journal of Thoracic and Cardiovascular Surgery
Controlled hypothermic storage of donor organs at 10°C is an emergent clinical standard in lung transplantation due to its superior graft protective effects. Itaconate, a known regulator of cell immunometabolism, has been shown to be upregulated in donor lungs preserved at 10°C for extended periods of static storage versus on ice. We hypothesized that itaconate may be an active agent in donor graft protection against ischemia-reperfusion injury, rather than a byproduct of 10°C graft metabolism. We conducted cell-based screening of multiple formulations and concentrations of itaconate and its derivatives and identified 0.25 mM dimethyl itaconate as the most promising candidate for lung preservation. Lungs from Yorkshire pigs (n = 4/group) were randomized to be flushed with low potassium dextran solution ± 0.25 mM dimethyl itaconate, stored at 4°C for 36 hours to limit endogenous itaconate production, then assessed using ex-vivo lung perfusion. Lungs preserved with dimethyl itaconate had better function, as indicated by lower airway pressures, higher lung compliances, improved perfusate oxygenation, and less edema formation than controls. Perfusate pro-inflammatory cytokines were significantly lower with dimethyl itaconate. Tissue IκBζ levels declined, and dimethyl itaconate prevented tissue oxidative stress after reperfusion. High resolution respirometry indicated no inhibition of succinate dehydrogenase with dimethyl itaconate at 0.25 mM at either hypothermic or normothermic conditions. Dimethyl itaconate safely modulated inflammation and improved lung physiologic performance upon reperfusion, supporting itaconate's protective role in donor-lung preservation.